Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$338.54
Open:$339.88
Day's Low:$339.00
Day's High:$356.35
Bid / Ask:-
Market Cap:16.95B
Enterprise Value:19.05B
52-Week Range
52-Week Low:$146.20
52-Week High:$379.63
Current position in 52-week range
52w Low-52w High
50-Day Avg:$302.78
200-Day Avg:$222.36
Volume
Volume Today:1,509,158
Avg Volume (3m):1,047,645
Avg Volume (10d):1,514,710
52-Week Change:+90.35%
vs S&P 500, 52 weeks:-
Beta:1.34
Valuation Multiples
P/E (trailing):n/a (loss)
Diluted EPS for the last 12 months: the four quarters ended Jun 27, 2026, from the accounts filed with the SEC on Aug 5, 2026. With negative EPS a P/E means nothing, so it is not shown.
P/E (forward):27.61
PEG Ratio:0.12
Price / Book:5.91
Price / Sales (TTM):4.24
EV / Revenue:4.76
EV / EBITDA:22.44
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):4.00B
Gross Profit:1.38B
EBITDA:849.12M
Net Income (TTM):−238.46M
Rev Growth (YoY):-2.70%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$-4.79
Diluted EPS for the last 12 months: the four quarters ended Jun 27, 2026, from the accounts filed with the SEC on Aug 5, 2026. With negative EPS a P/E means nothing, so it is not shown.
EPS Forward (Est.):$12.75
Revenue Per Share:$81.86
Cash Per Share:-
Book Value:$59.50
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:192.02M
Total Debt:3.03B
Net Debt (Debt - Cash):2.84B
Debt / Equity:105.05%
Current Ratio:1.35
Quick Ratio:0.80
Cash Flows
Operating Cash Flow:582.15M
Free Cash Flow (FCF):468.86M
FCF Yield (FCF / Market Cap):-
Enterprise Value:19.05B
EV / Revenue:4.76
EV / EBITDA:22.44
Profitability
ROE (Return on Equity):-7.52%
ROA (Return on Assets):4.11%
P/E (trailing):n/a (loss)
P/E (forward):27.61
Price / Book:5.91
PEG Ratio:0.12
52-Week Change:+90.35%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$-4.79
Diluted EPS for the last 12 months: the four quarters ended Jun 27, 2026, from the accounts filed with the SEC on Aug 5, 2026. With negative EPS a P/E means nothing, so it is not shown.
EPS Forward (Est.):$12.75
P/E (forward):27.61
PEG Ratio:0.12
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$81.86
Cash Per Share:-
Book Value:$59.50
Cash Flows (TTM)
Free Cash Flow:468.86M
Operating Cash Flow:582.15M
EBITDA:849.12M
Total Revenue (TTM):4.00B
Net Income (TTM):−238.46M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:48,167,730
Float (free shares):47,196,558
Short interest (shares):2,834,023
Short % of float:-
Short Ratio (days to cover):2.77
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Charles River Laboratories International, Inc. (CRL) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Corporate Executive Vice President of Corporate Development & Strategy
51
1.25M
Ms. Victoria L. Creamer
Corporate Executive VP & Chief People Officer
55
1.23M
Mr. Glenn G. Coleman CPA
Corporate Executive VP & CFO
57
-
Mr. Mark Mintz
Corporate EVP, Chief Information Officer & Global Shared Services
51
-
Mr. Todd Spencer
Corporate Vice President of Investor Relations
-
-
Ms. Kerry Dailey
Corporate Senior VP & Chief Legal Officer
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Charles River Laboratories International, Inc. (CRL): Quantitative Analysis
Charles River Laboratories International, Inc. (CRL) — Healthcare — Diagnostics & Research. CRL is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, CRL has returned +76.4% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
CRL ranks 383 of 461 on today's multifactor score, and 49 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.28, ranked 46 of 494); its weakest is quality (Z -0.92, ranked 448 of 468). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Frequently asked questions about Charles River Laboratories International (CRL)
When does Charles River Laboratories International report earnings?
According to Nasdaq's public calendar (checked on Nov 4, 2026), Charles River Laboratories International will report its next earnings on Nov 4, 2026, before the US market opens. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 12 before the open (SEC filings through Aug 5, 2026). CRL earnings dates and times, quarter by quarter →
Where does Charles River Laboratories International rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Charles River Laboratories International ranks 383 of 461, and 49 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Charles River Laboratories International insiders bought or sold shares?
The latest open-market purchase of Charles River Laboratories International shares filed with the SEC (Form 4) was on Sep 30, 2026, by an officer, for $3k. The latest sale was on Oct 22, 2026, by a director, for $8.4M. In total, from August 2025 through Nov 3, 2026: 2 purchases and 14 sales by directors, officers and large shareholders. All CRL insider trades →
What sector is Charles River Laboratories International in, and which index?
Charles River Laboratories International is classified in the Healthcare sector (industry: Diagnostics & Research), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.